Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2006

Januvia(Sitagliptin Phosphate)Merck & Co., Inc. logoMRK

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Merck & Co., Inc.

$3.81B

Medicare cost, 2024

Medicare drug plans spent $3.8 billion on Januvia (sitagliptin phosphate) in 2024, for 4.0 million prescriptions and refills filled by 827,991 patients. It ranks 12th among all drugs by Medicare drug plan spending. California accounts for the most spending ($434.3 million, 11% of the total). It is made by Merck & Co., Inc. (MRK).

Medicare cost, 2024

$3.81B

-6.9% from 2023

Prescriptions

4.0M

$945.51 per claim

Patients

828K

231,789 prescribers

Total spending, 2024

$3.81B

$4,597.26 per patient

Questions and answers

How much does Medicare spend on Januvia?

Medicare prescription drug plans paid $3.81B for Januvia in 2024, for 4,025,920 prescriptions and refills to 827,991 patients (down 6.9% from 2023). The average cost per claim was $945.51.

Which state spends the most on Januvia?

California had the highest Medicare cost for Januvia in 2024: $434.3M for 461,907 claims, followed by New York ($389.8M).

Who prescribes Januvia the most?

Bin Wang, internal medicine in Flushing, NY, had the highest Medicare cost for Januvia in 2024: 1,165 claims costing $886K.

Who makes Januvia?

Januvia is made by Merck & Co., Inc. (MRK), listed in the Medicare spending data as Merck Sharp & D.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Januvia was $3.81B in 2024, after a high of $4.10B in 2022.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Januvia, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Bin Wang Flushing, NYInternal Medicine1,165164$886K
Kelvin Mai Santa Ana, CAInternal Medicine946160$739K
Rodolfo Guzman Bronx, NYEndocrinology649150$706K
Hossam H Amin Brooklyn, NYPulmonary Disease940131$676K
Xiangsheng Zheng Birmingham, ALInternal Medicine1,101138$634K
Stella Ilyayeva Rego Park, NYInternal Medicine877165$626K
Jose L Vega III Yuma, AZFamily Practice461142$550K
Sonwoo Lee Los Angeles, CAInternal Medicine81898$531K
Saleh Khaddash Clifton, NJEndocrinology537135$521K
Jose R Baez Lawrence, MAInternal Medicine825150$509K
Pankaj Shukla Bakersfield, CAInternal Medicine618115$504K
Mauricio E Jimenez El Paso, TXInternal Medicine350111$495K
Ajay G Meka Santa Ana, CAInternal Medicine441130$474K
Eugenio Angueira-Serrano Miami, FLEndocrinology675151$468K
Paul H Deutsch Norwich, CTInternal Medicine36689$468K
Benito A Marranzini El Paso, TXEndocrinology359124$467K
Jason S Paek Rowland Heights, CAInternal Medicine646103$463K
Pankaj V Patel Edison, NJInternal Medicine45098$457K
Stanley Kim Edison, NJNephrology56685$453K
Jaime F Lopez-Santini New York, NYInternal Medicine37294$448K
Paramjit S Takhar Sacramento, CAFamily Practice411108$446K
Sixto R Caro Brooklyn, NYInternal Medicine51194$441K
Muhammad Bakleh Flint, MIEndocrinology440112$433K
Mohammad A Chaudhry Union City, NJInternal Medicine41987$432K
Yong S Lin New York, NYInternal Medicine52677$429K

Prescriber data by year

YearPrescribersClaimsPatientsCost
2022231,0374,241,351884,560$4.10B
2023230,8184,027,265842,948$4.09B
2024231,7894,025,920827,991$3.81B

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Merck Sharp & DMRK logoMRK4,027,317$3.81B

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
24
RxNorm concept IDs
2709603, 2709608, 2709612, 665036, 665040
Application numbers
NDA021995

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube